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Case report
Massive pleural effusion attributed to high-dose cyclophosphamide 
during conditioning for BMT
N Schaap1, R Raymakers1, A Schattenberg1, JP Ottevanger2  and T de Witte i
1Division of Hematology, University Hospital Nijmegen; and ~Netherlands Centre for Monitoring of Adverse Reactions to Drugs, 
Rijswijk, The Netherlands
Summary:
A 37-year-old male developed massive pleural effusion
(TBI) was given in two equal fractions of 450 cGy each 
Infection prophylaxis consisted of eotrimoxazole 960
two cipr n /i
leading to respiratory failure and electromechanical dis- times daily, aciclovir 400 mg four times daily, ampho- 
sociation within 24 h after the second dose of 4200 mg tericin-B inhalations 5 mg two times daily. Ondansetron
cyclophosphamide (CY) during conditioning for alio- mg was given two times daily. On day - 4
geneic bone marrow transplantation for chronic myelo- last CY he complained of pain in his right shoulder radiat-
genous leukemia. After resuscitation and bilateral pleu- ing to the right arm. Physical examination showed no
ral drainage he recovered within 1 day. Subsequently, abnormalities, body temperature was 37.2°C and laboratory
total body irradiation was given and with a delay of 1 findings were all normal. The pain persisted and 24 h later
day the transplantation procedure was continued with- he experienced chest pain which was not related to respir-
out major complications. No explanation for this idio- ation.
syncratic reaction other than the administration of high pelature and pulmonary examination remained normal. A
dose CY in combination with mesna rescue was found. chest X-ray showed bilateral pleural effusion without intra-
This reaction has not been reported before in the litera- pulmonary signs. Arterial blood values were p()„■>'. 6.9 kPa
Within
ture.
Keywords: pleural 
marrow transplantation
(N 10.6-13.3 kPa), pC 02: 5.9 kPa (N « 4.5-6.0 kPa), pH
cyclophosphamide; bone 7.48 (N = 7.38-7.43), bicarbonate 33.2 mmol/î (N
26 mmol/1). Since overhydration was considered 
with diuretics and oxygen was initiated ( 120 mg 
i.v., 4 1 0 2/min). Three hours later he deteriorated with sev-
A 37-year-old man suffering from Philadelphia chromo­
some positive chronic myelogenous leukemia in 
chronic phase was admitted for bone marrow transplan­
tation with marrow from his HLA-identical, MLC-negative 
sister. At admission the patient had no complaints and 
physical examination and laboratory findings were com­
pletely normal. A double-lumen catheter was introduced in 
the left subclavian vein without complications. Twenty-four
1 ater if* with
demethoxydaunorubicin 77 mg by continuous intravenous 
infusion over 48 h (day -12  and -11). Hyperhydration (3 
1 NaCl 0.45% glucose 2.5%/24 h) and alkalinization (1 1 
NaHCO., 4.2%/24 h) was started at day - 7  and continued 
until day -1. Cyclophosphamide (Endoxan®, Asta, Biele­
feld, Germany) 4200 mg on each of 2 consecutive days was 
given in a 1-h infusion by peripheral venous infusion. 
Mesna rescue was administered (at each time point 1400
3, 6, 9mg) with cyclophosphamide (days -6  and 
and 12 h thereafter. At days - 2  and -1 total body irradiation
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was 125/82 mmHg, pulse 138/min. No pulsus paradoxus 
was observed. Percussion of the lungs revealed 
pleural effusion. On auscultation 
over the right lung compared to left. Auscultation of the
art and
graphy showed sinus tachycardia ( 
size of the complexes in c 
Arterial blood analysis
normal. Electrocardio
with previous ECO,s. 
oxygen s
showed: p 0 2 10.3 kPa, pC 02 6.8 kPa, pH 7.44 and bicar­
bonate 34.5 mmol/1. Ultrasound of the heart showed normal
and r ventricular without pericardial
effusion. Massive bilateral pleural fluid was seen 
echocardiography the patient suffered cardiopulmonary 
arrest with electromechanical 
was started immediately. After 30 min cardiac output was 
restored and the patient regained consciousness. Perfusion 
scintigraphic investigation of the lungs showed bilateral 
defects confluent with the pleural effusions, but no signs 
of embolism.
Pleural drainage was performed and 5 1 of transparent 
pleural fluid were evacuated. Biochemical analysis revealed 
protein content: 2.68 g/1; LDH 32 U/l; amylase 3 U/l; glu­
cose 52 mmol/1 (serum glucose 38 mmol/1); triglycerides 
0.24 mmol/1; leukocytes 0/lield; erythrocytes 4/lìeld. Viro-
Pleural effusion during conditioning for BMT
N Schaap et al
logical investigations revealed CMV early antigen and anti- (VOD) after conditioning with busulphan and cyclophos- 
gen negative; respiratory, adeno-, and enteroviruses all phamide. In this patient no busulphan was used and no 
negative. All cultures for bacteria and fungi were negative. signs of VOD were present.
Digital subtraction angiography 
excluded pulmonary embolism.
pleural drainage Mesna has been well tolerated by all our patients up to
now. High-dose mesna (>60 per can produce
After drainage respiratory failure resolved. The patient gastro-intestinal eg nausea, vomiting and
was extubated 10 h after resuscitation. The drains produced and all of these symptoms are difficult to dis­
no significant amounts of fluid after 16 h and were tinguish from sidc-elTects produced by CY. The dose we 
removed. Chest X-rays showed only minimal residual pleu- use as CY rescue was only 20 mg/kg. No data are available
during mesna therapy in combination 
with oxazaphosphyrines such as CY. In more than 150 pati­
rai fluid on the left side which completely resolved after 3 on pleural 
days, and no intrapul mo nary abnormalities.
Because of the rapid recovery, we decided to proceed ents conditioned with a regimen consisting of Ida, CY and 
with the conditioning regimen. TBI was given without TBI we have never seen acute cardiac or acute pulmonary 
further complications (4.5 Gy on each of 2 consecutive 
days). A T cell-depleted marrow graft1 was given 1 day
toxicity during or alter administration ot demethoxydauno­
rubicin.8 Demethoxydaunorubicin (42 mg/m2) is adminis-
after the last irradiation. On day 15, his granulocyte count tered as a continuous infusion over 48 h. A relation between
was >500 x 10c71 and he became transfusion independent. demethoxydaunorubicin and
. . . .  . A  O  fe d  It A
'al has never
He developed mild grade II graft-versus-host disease of the been reported in the literature. The time between aclminis 
skin and liver. On day 21 he was discharged in good con- trat ion of the drug and the first symptoms (6 days) does not
BMT make a direct causal relation very likely. A late interaction,
out any pulmonary abnormalities and in remission from however, between metabolites of demethoxydaunorubicin 
CML. and high-dose cyclophosphamide could be possible.
In patients with chest pain and progressive dyspnea after 
administration of high-dose CY the possibility of massive 
pleural effusion should be considered, with pleural drainage 
as a life-saving procedure.
Discussion
We hypothesize that the high dose cyclophosphamide alone 
or in combination with mesna was responsible for the reac­
tion described. All prophylactic medication given during 
conditioning was continued after the incident without 
adverse effects. An interaction between cyclophosphamide 
and one of these agents can not be completely ruled out. 
We found no evidence of an infectious agent. Overhydra­
tion was unlikely. The body weight was stable before the 
incident and fluid balance was adjusted. He had no symp­
toms of peripheral edema and no signs of intrapulmonary 
overhydration or congestive heart failure. Diuretics did not 
improve his condition nor prevented further progression.
Diffuse myocardial injury with progressive congestive 
heart failure is a well known subacute complication of high- 
dose cyclophosphamide therapy. In such patients myocar­
ditis has been documented with typical pathologic findings. 
Fibrinoid pericarditis is also a common finding. The inci­
dence of this complication varies between 7-25%. A corre­
lation has been established between incidence and total 
dose of cyclophosphamide administered.2"5 Angelucci et al6 
described eight thalassémie patients with cardiac tampon­
ade caused by pericardial effusion with physiochemical 
characteristics of transudate after high-dose CY. They con­
cluded that the absence of myocardial lesions and complete 
resolution of the syndrome after fluid removal strongly 
indicated that the pericardial membranes played the main 
part of the pathogenesis of the syndrome.
In the patient described, no myocardial or pericardial 
involvement was seen but the underlying mechanism may 
be similar. Ozkaynak et aV  observed a high incidence of 
pleural effusion in children with veno-occlusive disease
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